Alterity Therapeutics Limited

NASDAQ:ATHE

Biotechnology

Healthcare
$3.12 +9.89%

+$0.53 today

Market cap
$52.77M
Beta
-0.03
P/E (TTM)
-9.9
EPS (TTM)
-$0.07
52W Low $2.66High $7.00

Volume 0.02M

Average 0.05M

ATHE EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Alterity Therapeutics LimitedNASDAQ: ATHE

EBITDA · Q2 FY2026 · quarter ended Dec 2025

EBITDA remains negative

Q2 FY2026 EBITDA was -A$12.76M, compared with -A$7.53M a year earlier.

Context

  • EBITDA amounted to 269.0% of revenue in FY2025, down 217.9 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of -A$6.84M (+53.3%) for the fiscal year ending Jun 2026, a step up from the +25.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-A$12.76M— QoQ
Last fiscal yearJun 2025
-A$14.63M+25.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-69.6%——
1 year+25.2%+53.3%+28.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

AUD · from the income statement

Latest · FY2025
(14.63M) AUD
Year-over-year change
+25.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ATHE compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +25.2% is the highest of 4, against a peer median of -50.5%.
  • EBITDA amounts to 269.0% of revenue for ATHE, versus a peer median of 230.3%.
ATHE Competitors
EBITDA for ATHE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DYAIDyadic International, Inc.LTM Mar 2026-$6.85M USD-29.2%—230.3%
ATHEAlterity Therapeutics LimitedFY2025-A$14.63M AUD+25.2%—269.0%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026-$14.89M USD-54.8%——
ANVSAnnovis Bio, Inc.LTM Mar 2026-$40.92M USD-50.5%——
Peer median (excluding ATHE) —-50.5%—230.3%

Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue4.34M5.12M3.92M4.02M5.44M
Cost of Revenue360.03K364.67K285.07K214.3K127.52K
Gross Profit3.98M4.76M3.63M3.8M5.31M
Gross Margin91.7%92.9%92.7%94.7%97.7%
Research & Development12.28M14.75M13.2M18.64M14.4M
Selling, General & Admin6.87M5.51M5.04M4.76M5.48M
Operating Expenses19.16M20.26M18.24M23.41M19.89M
Depreciation & Amortization18.66K54.21K37.85K35.34K28.31K
EBITDA(15.16M)(17.39M)(14.6M)(19.57M)(14.63M)
EBITDA Margin-349.3%-339.5%-372.8%-486.9%-269.0%
Operating Income(15.18M)(15.5M)(14.64M)(19.6M)(14.57M)
Operating Margin-349.8%-302.6%-373.7%-487.7%-268.0%
Interest Income20.68K2.5K16.44K268.42K446.29K
Interest Expense00000
Other Income / Expenses(133.04K)2.72M904.68K524.33K2.49M
Income Before Tax(15.31M)(12.78M)(13.7M)(19.08M)(12.08M)
Pre-Tax Margin-352.8%-249.4%-349.9%-474.6%-222.1%
Income Tax Expense(3.08M)70.01K104.46K46.09K68.06K
Net Income(15.31M)(12.85M)(13.81M)(19.12M)(12.15M)
Net Margin-352.8%-250.7%-352.5%-475.8%-223.4%
EPS (Basic)(5.40)(3.18)(3.42)(3.12)(1.14)
EPS (Diluted)(5.40)(3.18)(3.42)(3.12)(1.14)
Weighted Avg Shares2.83M4.01M4.05M6.08M10.66M
Weighted Avg Shares (Diluted)2.83M4.01M4.05M6.08M10.66M

Alterity Therapeutics Limited

NASDAQ:ATHE

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.